Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Pacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
August 3, 2018 6:57 AM EDTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform rating.
Analsyt Gary Nachman commented, "PCRX reported 2Q18 non-GAAP revenue of $81mmabove BMO/consensus $77mm/$76mm, and EPS of $0.24 above BMO/consensus $0.09/$0.07. Solid 2Q... More
Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
August 2, 2018 8:14 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.24, $0.17 better than the analyst estimate of $0.07. Revenue for the quarter came in at $80.43 million versus the consensus estimate of $78.86 million.
Second Quarter 2018 Financial Results
EXPAREL net product sales were $80.4 million in the second quarter of 2018, a 15% increase over the $69.8 million reported for the second quarter of 2017. Total operating expenses were $77.6 million in the second quarter of 2018, compared to $86.7 million in the second quarter of 2017. GAAP net income was $2.6 million, or $0.06 per share (basic and diluted), in the second... More